Dejucq N
Wohl Virion Centre, Windeyer Institute of Medical Sciences, London, United Kingdom.
J Leukoc Biol. 2000 Sep;68(3):331-7.
We studied the replication of HIV-1 macrophage-tropic CCR5-using strains (R5) in CD4+ T cell lines to better understand the switch in co-receptor use of such strains during disease progression and to assess resulting changes in cell tropism. We found that the majority of R5 strains cannot replicate in CD4+ T cell lines without adaptation by serial passage. A small minority of primary R5 isolates, however, were able to infect two T cell lines, Molt4 and SupT1. This expanded tropism was due to the use of undetectable levels of CCR5 rather than CXCR4 or alternative receptors. In contrast, HIV-1sF162 adaptation for replication in the C8166 T cell line was due to the emergence of variant strains that could use CXCR4. Of two variants, one was dual-tropic and one T-tropic, although both could use CCR5 as well as CXCR4. A single mutation in the start codon of the accessory gene vpu accounted for the T-tropic phenotype of the second variant, indicating that a non-functional vpu impairs macrophage tropism. Thus, in vitro and in the absence of an immune response, R5 strains naturally adapt to infect CXCR4+ T cell lines. Such adaptation resembles the rare R5 to X4 switch that occurs in vivo. Mutations in accessory genes (e.g., vpu) not required for replication in rapidly dividing cell lines may also occur in vitro, abrogating replication in primary cell types such as macrophages. Such mutations, however, are normally selected against in vivo.
我们研究了嗜巨噬细胞的HIV-1 CCR5利用株(R5)在CD4+ T细胞系中的复制情况,以更好地理解此类毒株在疾病进展过程中辅助受体使用的转变,并评估由此导致的细胞嗜性变化。我们发现,大多数R5毒株若不经连续传代适应,无法在CD4+ T细胞系中复制。然而,一小部分原代R5分离株能够感染两种T细胞系,即Molt4和SupT1。这种嗜性扩展是由于使用了检测不到水平的CCR5,而非CXCR4或其他替代受体。相比之下,HIV-1 sF162在C8166 T细胞系中复制的适应性是由于出现了能够使用CXCR4的变异株。在两个变异株中,一个是双嗜性的,一个是T嗜性的,尽管两者都能使用CCR5以及CXCR4。辅助基因vpu起始密码子中的一个单突变导致了第二个变异株的T嗜性表型,表明无功能的vpu会损害巨噬细胞嗜性。因此,在体外且无免疫反应的情况下,R5毒株会自然适应感染CXCR4+ T细胞系。这种适应类似于体内罕见的R5向X4的转变。在快速分裂细胞系中复制不需要的辅助基因(如vpu)中的突变在体外也可能发生,从而废除在原代细胞类型(如巨噬细胞)中的复制。然而,此类突变在体内通常会被淘汰。